Correction: Nelson et al. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers 2021, 13, 1566

Nelson, Ryan S.Seligson, Nathan D.Bottiglieri, SalCarballido, EstrellaDel Cueto, AlexImanirad, ImanLevine, RichardParker, Alexander S.Swain, Sandra M.Tillman, Emma M.Hicks, J. Kevin2024-12-062024-12-062024-10-25Nelson RS, Seligson ND, Bottiglieri S, et al. Correction: Nelson et al. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers 2021, 13, 1566. Cancers (Basel). 2024;16(21):3595. Published 2024 Oct 25. doi:10.3390/cancers16213595https://hdl.handle.net/1805/44790en-USAttribution 4.0 InternationalUGT1A1PharmacogeneticsIrinotecanPazopanibNilotinibBelinostatCancerGenotypePrecision medicineGilbert’s syndromeCorrection: Nelson et al. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers 2021, 13, 1566Article